0.01). ACTH and cortisol responses to ghrelin or CRH were similar in CD patients. Combined ghrelin + CRH administration in CD patients produced the highest ACTH response (peak and AUC 0-120 min ) compared to ghrelin or CRH alone (p < 0.01). Cortisol responses after ghrelin + CRH were uncoupled with ACTH responses and similar to the response to ghrelin or CRH alone in both groups. ACTH and cortisol responses, during all three tests, were similar in CD patients with micro-or macroadenomas. Conclusion: Ghrelin administration causes exaggerated ACTH and cortisol responses in CD patients compared to healthy controls. In combination with CRH, it additionally enhances ACTH secretion without further additive effect on cortisol output.
trophic stimuli. This is reflected in their adrenocorticotropic hormone (ACTH) and cortisol responses to corticotropin-releasing hormone (CRH), arginine vasopressin (AVP) and its synthetic analogues and partial cortisol suppression after high-dose dexamethasone administration. Following the discovery of growth hormone secretagogues (GHS), their receptor (GHS-R) and their natural ligand ghrelin, the gut-brain neuropeptide, it has been shown that these molecules, apart from stimulating GH secretion, have significant ACTH-and cortisol-releasing properties [1] [2] [3] [4] [5] . Subsequently, this led to the discovery of exaggerated ACTH and cortisol responses to GHS and ghrelin in patients with Cushing's disease (CD) [6] [7] . Patients with adrenal Cushing's syndrome do not respond to GHS and ghrelin, while responses in patients with ectopic ACTH secretion are variable since some of these neuroendocrine tumors express GHS-R [3, [6] [7] [8] [9] . Previous studies have suggested different mechanisms of action of CRH and synthetic GHS in the regulation of ACTH secretion in both healthy individuals and CD patients. However, ghrelin has not been used in combination with CRH in patients with CD. The aim of our study was to investigate ACTH and cortisol responses to ghrelin alone or in combination with CRH in patients with CD and compare them to those of healthy individuals matched for age, sex and BMI.
Patients and Methods
We assessed a cohort of 21 patients (18 females, 3 males) with CD (mean age 49.8 ± 10.2 years, BMI 29.8 ± 0.8). Diagnosis of CD was confirmed by dynamic testing in all patients, on the basis of persistent hypercortisolemia, low-dose dexamethasone suppression test, and positive ACTH and cortisol responses in the CRH test. In all patients, we performed the following tests: (1) ghrelin alone (acylated human ghrelin 100 μg i.v. bolus; Bachem, UK), (2) CRH alone (human CRH 100 μg i.v. bolus; Fering, Sweden), and (3) ghrelin + CRH combination, each 1 week apart. Samples were taken at 0, 15, 30, 45, 60, 90 and 120 min after administration of ghrelin and/or CRH and stored at -80 ° C until assayed for ACTH and cortisol by commercially available kits. Magnetic resonance imaging disclosed pituitary macroadenoma in 10 and microadenoma in 11 patients with CD. Pituitary ACTH adenoma was histologically confirmed in all CD patients harboring macroadenomas and in 8 with microadenomas. In the remaining 3 patients, the operated tissue was insufficient for histological diagnosis. None of the patients were treated medically for hypercortisolism and all had active CD at the time of the investigation. The control group consisted of 8 healthy subjects (7 females and 1 male) matched for age (40.6 ± 5.3 years) and BMI (29.9 ± 1.2), recruited from the obesity outpatient clinic, in whom hypercortisolism was excluded by normal suppression of cortisol with 1 mg of dexamethasone given orally at midnight. No patients and no control subjects were receiving any drugs known to affect the hypothalamo-pituitary-adrenal (HPA) axis.
Hormone Assays
Plasma ACTH was measured by enzyme-linked immunosorbent assay (Cis Bio International, France), coefficient of variation intra-assay 3.7% and inter-assay 3.8%. Serum cortisol was measured by commercially available radioimmunoassay kits (Cis Bio International), coefficient of variation inter-assay 4.7% and intraassay 4.2%.
Statistical Analysis
All values are expressed as mean ± SEM. Two-way ANOVA was used, followed by Wilcoxon's and Friedman's tests to analyze differences in hormonal responses to different stimuli. The area under the curve (AUC 0-120 min ) was calculated using the trapezoidal rule. Percent of rise from baseline to peak ACTH values was also calculated. A p value <0.05 was considered statistically significant. Statistical analysis was performed using the software SPSS for Windows v. 20.0.
Statement of Ethics
Informed consent was obtained from all participants. The institutional ethics committee approved the study.
Results
Clinical characteristics of the investigated subjects are presented in table 1 . At baseline, ACTH ( fig. 1 ) and cortisol levels ( fig. 2 ) were significantly higher in patients with CD compared to controls (p < 0.01). After stimulation with ghrelin and/or CRH, peak and AUC 0-120 min values of ACTH and cortisol were also significantly higher in patients with CD compared to control subjects (p < 0.01).
In CD patients and controls, ACTH ( fig. 1 ) and cortisol ( fig. 2 ) responses (peak and AUC 0-120 min values) to ghrelin administration were similar to those observed after CRH administration. Combined ghrelin + CRH administration was superior to ghrelin or CRH alone in CD patients and produced the highest ACTH responsespeak and AUC (p < 0.01, fig. 1 ). The highest rise in ACTH secretion (peak and AUC) was also registered following fig. 1 ). However, this remarkable ACTH response induced a cortisol response similar to that observed after administration of either ghrelin or CRH alone in both groups ( fig. 2 ) .
When individual peak ACTH responses to combined stimulation with ghrelin + CRH were analyzed, different patterns of response were observed. Synergistic, additive or less than additive responses were found in both groups.
Individual ACTH responses to combined stimulation with ghrelin + CRH were determined as (1) additive if: equal to or greater than the arithmetic sum of peak ACTH responses after CRH alone and ghrelin alone but not exceeding the sum of peaks by more than 50%, (2) less then additive if: less than the arithmetic sum of peaks, i.e., similar to peak ACTH responses after CRH alone or ghrelin alone, and (3) synergistic if: ≥ 50% higher than the arithmetic sum of peak ACTH responses after CRH alone and ghrelin alone. When individual peak ACTH responses were analyzed, the synergistic pattern of response was more prevalent in patients with CD compared to healthy controls (57.1 vs. 25.0%), while additive responses were more common in healthy subjects compared to CD (75.0 vs. 42.9%; table 2 ). Using the same criteria, the mean values of AUC and peak ACTH responses to combined stimulation with ghrelin + CRH were determined and were deemed additive in both groups. However, they were significantly higher in patients with CD compared to con- 37 trols (p < 0.01). ACTH and cortisol responses, during all three tests, were similar in CD patients with micro-and those with macroadenomas (data not shown).
Discussion
Our results confirm exaggerated ACTH and cortisol responses to ghrelin, alone or in combination with CRH, in CD patients compared to healthy controls, and further expand the insight in the pathophysiology of tumoral corticotroph secretory behavior.
In healthy individuals, ACTH secretion is stimulated at the hypothalamic level by CRH and AVP signals integrating the pulsatile diurnal rhythm with stress and feeding responses.
Since the ACTH-releasing activity of GHS and ghrelin is sensitive to negative glucocorticoid feedback in healthy individuals and in patients with ACTH-independent Cushing's syndrome [3] , it is remarkable and intriguing that in patients with CD, despite chronic hypercortisolism, responsiveness to ghrelin and GHSs is exaggerated [6, 7, 10, 11] . Overexpression of ghrelin receptors in corticotroph adenoma cells may at least in part account for this finding [12] [13] [14] [15] . Expression of ghrelin and its receptor in the hypothalamus and pituitary has also been shown, suggesting its role in the regulation of the HPA axis at both the hypothalamic and pituitary level [16] [17] [18] . Furthermore, autocrine and paracrine effects of ghrelin on ACTH-producing cells cannot be excluded since colocalization of ACTH and ghrelin in the same vesicles of corticotrope adenoma cells has been shown by MartinezFuentes et al. [19] .
Only two previous studies have investigated the ACTH and cortisol responses after combined administration of GHS hexarelin + CRH in healthy subjects [20] and patients with CD [10] . Korbonits et al. [20] have shown that in healthy subjects, hexarelin stimulates the HPA axis independently of CRH, while Arvat et al. [10] reported additive mean ACTH responses after combined CRH + hexarelin administration in 8 female patients with CD. In the study by Pecori-Giraldi et al. [21] , the ACTH response elicited by ghrelin in cell cultures of human ACTH-secreting pituitary adenoma cells was significantly less than the one induced by CRH, suggesting that the marked ACTH response to ghrelin in patients with CD is due at least in part to its action on the pituitary tumor, but that additional hypothalamic mechanisms must also be involved in the in vivo response. In line with this are findings from in vitro animal studies of potent AVP-, CRHand neuropeptide Y-releasing effects of ghrelin from rat hypothalamic explants [22] [23] [24] . These complex interactions may account for synergistic effects of CRH and ghrelin on ACTH release at the hypothalamic and pituitary level.
In our study, we have observed prevalently synergistic individual ACTH responses after combined CRH + ghrelin administration in patients with CD. There are several possible explanations for this: (1) administration of ghrelin may directly or indirectly stimulate hypothalamic CRH and/or AVP neurons, causing synergistic effects, (2) inhibition of somatostatinergic tone may also increase the ACTH response to ghrelin + CRH, as shown by Iranmanesh et al. [25] , and (3) GHS receptor status in ACTHsecreting pituitary adenoma cells has been shown to correlate with in vivo responses of CD patients to GHS administration and may account for variable ACTH responses to ghrelin [26] irrespective of their size.
Cortisol responses in our study were similar in all three tests and not amplified further by combined ghrelin + CRH administration. A non-linear ACTH to cortisol response has also been reported in previous studies with co-administration of ghrelin or hexarelin + CRH [10, 20, 25] . These data suggest uncoupling of ACTH and cortisol after achieving maximal cortisol values similar to that observed in states of psychological or physical stress [27] or during pharmacological stimulation [28] . Correa-Silva et al. [29] have tested ACTH and cortisol responses to growth hormone-releasing peptide 6 and ghrelin in patients with CD before and after 6 months of treatment with the cortisol-lowering drug ketoconazole. According to the authors, significant decrease in cortisol levels, after ketoconazole treatment, was accompanied by further increase in ACTH responses to hormone-releasing peptide 6 and ghrelin, indicating recovery of healthy, previously suppressed corticotroph cells.
The strength of this study is that we included more patients with CD than the previous studies, and for the first time, we showed synergistic effects in over half of these patients when CRH and ghrelin were combined, using human acylated ghrelin and CRH at doses found to induce maximal dose-response effects. The number of the included healthy controls was limited due to the limited availability of ghrelin; however, the control group was very well matched (for age, sex and BMI). Other factors such as the price of ghrelin + CRH may limit its use in routine clinical practice. Expression of ghrelin receptors in some neuroendocrine tumors with ectopic ACTH secretion may reduce its potential for use in the differential diagnosis of ACTH-dependent Cushing's syndrome. 38 In conclusion, our data indicate that ghrelin causes exaggerated ACTH and cortisol responses in patients with CD and that in combination with CRH it may further enhance ACTH secretion without having a similar effect on cortisol output. Furthermore, our data suggest that variability in the hypothalamo-pituitary responsiveness and receptor status may account for individual differences in ACTH responses to ghrelin alone or in combination with CRH in patients with CD.
